Novo Nordisk launches weightloss drug Wegovy in India at competitive prices, facing patent battles and high demand.

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

A $10.2 million savings across more than 100,000 prescriptions over three months, extrapolated across the nearly 33 million Americans currently taking GLP-1 medications monthly, indicates a potential ...

Spain’s ministry of health has asked Novo Nordisk for clarification about a controversial obesity awareness campaign which may have broken the country’s law on promoting prescription drugs. The ...

Research out today is the latest to suggest that semaglutide can significantly lower people's risk of dementia.

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gained early traction. Both drugs address rising obesity and ...

Deepseek AI’s scare kicked off the year, rattling faith in the “Magnificent Seven” and the broader tech space. 💵💰Don't miss ...

Hims & Hers Health, a telehealth company, offers direct-to-patient platform to distribute prescription drugs and OTC ...

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

We wanted to price it in India in a way which is comparable to the therapies that are available,' said Vikrant Shrotriya, ...